JP2011517319A - メタロプロテアーゼ１２結合タンパク質 - Google Patents

メタロプロテアーゼ１２結合タンパク質 Download PDF

Info

Publication number
JP2011517319A
JP2011517319A JP2010549830A JP2010549830A JP2011517319A JP 2011517319 A JP2011517319 A JP 2011517319A JP 2010549830 A JP2010549830 A JP 2010549830A JP 2010549830 A JP2010549830 A JP 2010549830A JP 2011517319 A JP2011517319 A JP 2011517319A
Authority
JP
Japan
Prior art keywords
mmp
protein
binding protein
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010549830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517319A5 (enExample
Inventor
レーティティア デビー，
ソニア ショーンブラット，
ホート，レネ
ニコラ フラン，
Original Assignee
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2011517319A publication Critical patent/JP2011517319A/ja
Publication of JP2011517319A5 publication Critical patent/JP2011517319A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010549830A 2008-03-03 2009-03-03 メタロプロテアーゼ１２結合タンパク質 Withdrawn JP2011517319A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3334808P 2008-03-03 2008-03-03
US61/033,348 2008-03-03
US12783008P 2008-05-14 2008-05-14
US61/127,830 2008-05-14
PCT/US2009/035925 WO2009111507A1 (en) 2008-03-03 2009-03-03 Metalloproteinase 12 binding proteins

Publications (2)

Publication Number Publication Date
JP2011517319A true JP2011517319A (ja) 2011-06-02
JP2011517319A5 JP2011517319A5 (enExample) 2012-04-19

Family

ID=41056352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549830A Withdrawn JP2011517319A (ja) 2008-03-03 2009-03-03 メタロプロテアーゼ１２結合タンパク質

Country Status (6)

Country Link
US (1) US8114968B2 (enExample)
EP (1) EP2262530A4 (enExample)
JP (1) JP2011517319A (enExample)
AU (1) AU2009221915A1 (enExample)
CA (1) CA2717538A1 (enExample)
WO (1) WO2009111507A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533126A (ja) * 2012-10-05 2015-11-19 カドモン コーポレイション，リミティド ライアビリティ カンパニー ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
JP2018105726A (ja) * 2016-12-27 2018-07-05 株式会社国際電気通信基礎技術研究所 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法
WO2024090571A1 (ja) * 2022-10-28 2024-05-02 慶應義塾 Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404950B2 (en) 2003-02-18 2008-07-29 Baylor College Of Medicine Induced activation in dendritic cell
WO2005068020A1 (en) 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
CA3058450A1 (en) * 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
WO2010033949A1 (en) 2008-09-22 2010-03-25 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
WO2011130566A2 (en) * 2010-04-16 2011-10-20 Bellicum Pharmaceuticals, Inc. Method for treating solid tumors
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9750789B2 (en) * 2011-02-18 2017-09-05 The Trustees Of Columbia University In The City Of New York Use of matrix metalloproteinase inhibitors to treat tuberculosis
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
CN104302321A (zh) * 2011-12-05 2015-01-21 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
US9220759B2 (en) * 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2906676A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ， インコーポレイテッド Ｔ細胞増殖をコントロールするための方法
JP6467406B2 (ja) 2013-06-05 2019-02-13 ベリカム ファーマシューティカルズ， インコーポレイテッド カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
TWI819228B (zh) 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
ES3010561T3 (en) 2013-08-05 2025-04-03 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer including nsclc
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
WO2015157238A2 (en) * 2014-04-08 2015-10-15 Medimmune, Llc Binding molecules specific for il-21 and uses thereof
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
AU2015341481C1 (en) 2014-11-03 2021-09-16 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T cell receptors directed against Bob1 and uses thereof
CN115869398B (zh) 2015-09-24 2025-04-22 第一三共株式会社 抗garp抗体
EP3410849B1 (en) * 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
CA3054067A1 (en) 2017-03-14 2018-09-20 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic ph
CN118772278A (zh) 2017-06-02 2024-10-15 辉瑞公司 Flt3的特异性抗体及其用途
PE20210290A1 (es) 2018-03-21 2021-02-11 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
US11332546B2 (en) * 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2021222595A2 (en) * 2020-04-30 2021-11-04 Virtuoso Binco, Inc. Multispecific antibodies targeting cd38 and epcam and uses thereof
US20230183381A1 (en) * 2020-05-12 2023-06-15 Virtuoso Binco, Inc. Multispecific antibodies targeting cd38 and bcma and uses thereof
US20230391854A1 (en) * 2020-09-09 2023-12-07 Innovent Biologics (Suzhou) Co., Ltd. Monoclonal antibody for coronavirus spike protein, and use thereof
US20240288450A1 (en) * 2021-06-16 2024-08-29 Arizona Board of Regents on Behalf of the Univerity of Arizona Systems and methods for monitoring and treating stroke
CN118530365B (zh) * 2024-06-18 2025-03-11 辽宁得康药业集团有限公司 特异性检测mmp12蛋白的单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615976D0 (en) * 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
AU2003239132A1 (en) * 2002-04-08 2003-10-27 The Brigham And Women's Hospital, Inc. Methods and compositions for preventing and treating microbial infections
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
NZ540196A (en) * 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
EP1802331A2 (en) * 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
AU2006261357A1 (en) * 2005-06-17 2006-12-28 Zimmer Spine Austin, Inc. Improved method of treating degenerative spinal disorders
EP1931632A4 (en) * 2005-08-18 2011-05-11 Microbia Inc USEFUL INDOOR CONNECTIONS
WO2007024743A2 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533126A (ja) * 2012-10-05 2015-11-19 カドモン コーポレイション，リミティド ライアビリティ カンパニー ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
JP2018105726A (ja) * 2016-12-27 2018-07-05 株式会社国際電気通信基礎技術研究所 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法
WO2024090571A1 (ja) * 2022-10-28 2024-05-02 慶應義塾 Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬

Also Published As

Publication number Publication date
AU2009221915A1 (en) 2009-09-11
EP2262530A4 (en) 2012-12-05
US8114968B2 (en) 2012-02-14
CA2717538A1 (en) 2009-09-11
WO2009111507A1 (en) 2009-09-11
US20090311183A1 (en) 2009-12-17
EP2262530A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
US8114968B2 (en) Metalloproteinase-12 specific monoclonal antibody
US8013125B2 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) Metalloproteinase 9 binding proteins
JP2011517662A5 (enExample)
JP2011517320A5 (enExample)
JP2023159314A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
AU2011204349C1 (en) Plasma kallikrein binding proteins
US9051377B2 (en) Method for treating breast cancer using antibody binding to MMP-14
US20110135573A1 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
CN113271956A (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
CN110662766A (zh) Cd147抗体、可激活cd147抗体及其制备和使用方法
WO2010045388A2 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2009097397A2 (en) Metalloproteinase binding proteins
AU2019204295A1 (en) Plasma kallikrein binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131218